PolicyLatestStatnews5h ago

Gilead acquires Tubulis for over $3 billion

Gilead Sciences is purchasing cancer biotech Tubulis for more than $3 billion. This acquisition aims to enhance Gilead's oncology portfolio and expand its research capabilities.

Gilead Tubulis Biotech Research

0 upvotes

Source and timing

StatnewspublisherUpdated 4h ago

Open original source

What happened

Gilead Sciences is purchasing cancer biotech Tubulis for more than $3 billion.

Why it matters

This acquisition aims to enhance Gilead's oncology portfolio and expand its research capabilities.

Gilead acquires Tubulis for over $3 billion

More from this part of the feed

This update is standing on its own right now.